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erol prevented cardiomyocyte/capillary mismatch, and to someEffect of antioxidant therapy with dl--tocopherol on cardio-
extent also myocardial fibrosis in rats with renal failure. Thevascular structure in experimental renal failure.
results point to a role of oxidative stress in the genesis of myo-Background. Chronic renal failure is characterized by re-
cardial interstitial fibrosis and capillary deficit of the heart.modeling of the structure of the heart and the vasculature,
for example, left ventricular hypertrophy, myocardial fibrosis,
capillary/myocyte mismatch, as well as thickening of intramyo-
cardial arteries and of peripheral arteries and veins. Further- In view of the high incidence of cardiovascular deathmore, uremia is a state of increased oxygen stress. It was the
of uremic patients, structural changes of the heart andpurpose of this study to examine whether these findings are
the vasculature are of considerable interest [1, 2]. Clinicalinterrelated.
Methods. To investigate whether antioxidative therapy with observations documented various functional and struc-
dl--tocopherol (Toco; vitamin E) interferes with the develop- tural alterations of the heart and the extracardiac vessels
ment of abnormal cardiovascular structure in experimental [3–5]; cardiovascular remodeling has been documented
renal failure, 28 male Sprague-Dawley rats were subjected to
in subtotally nephrectomized (SNX) rats [6] and in ure-partial renal ablation (subtotal nephrectomy, SNX) or to sham
mic patients [7]. It is characterized by left ventricularoperation (sham). SNX were either left untreated or received
the antioxidant Toco (2 1500 IE/kg BW/week in the pellets). hypertrophy (LVH), hypertrophy of cardiomyocytes, ex-
Blood pressure was measured using tail plethysmography. The pansion of interstitial tissue, arteriolar wall thickening
experiment was terminated after 12 weeks. Heart and left ven- and diminished capillary supply. In particular, the myo-
tricular weight were determined and the following parameters
cyte/capillary mismatch is important because diminishedwere measured using morphometry and stereology: volume
capillary supply in the face of increased cardiomyocytedensities of cardiomyocytes, capillaries and non-vascular inter-
stitium; length density and total length of cardiac capillaries, mass must interfere with ischemia tolerance of the heart
wall thickness of intramyocardial arterioles and of the aorta. [7, 8]. Although the question of accelerated atherosclero-
Results. Systolic blood pressure and body weight were com- sis in patients with renal failure is still debated [9], an
parable in all groups. Treatment with Toco led to significantly
autopsy study found increased media thickness and theincreased plasma concentrations of Toco. Left ventricular
common presence of advanced stages of coronary plaquesweight and wall thickness of intramyocardial arteries were sig-
nificantly higher in both SNX groups compared to sham con- with heavy calcification in these patients [10]. The genesis
trols. Volume density of the cardiac interstitial tissue was sig- of the previously mentioned abnormalities is certainly
nificantly higher in untreated SNX than in Toco treated SNX complex, but they are not solely explained by classical
and sham control rats. Length density of capillaries was signifi-
cardiovascular risk factors, such as elevated blood pres-cantly lower in untreated SNX than in control rats; however,
sure, hyperlipidemia, smoking, hyperhomocysteinemia,the values were significantly higher, and even higher than in
sham controls, when SNX were treated with Toco. etc. A potential role of the sympathetic nervous system
Conclusions. Treatment with the antioxidant dl--tocoph- and particularly the endothelin system has been reported
[11, 12].
Increased oxidative stress has been reported in pa-Key words: left ventricular hypertrophy, myocardial fibrosis, cardiac
tients with renal failure [13–17]. Oxidative stress is knowncapillarization, microarteriopathy, oxidative stress, tocopherol, vita-
min E. to affect cardiovascular function, increase sympathetic
nervous activity [18], and enhance atherosclerosis pri-Received for publication May 2, 2001
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to be a crucial initial step in the adaptive remodeling of sumed the drug-loaded pellets completely. Systolic blood
pressure (SBP) was measured at the beginning of thevascular structures [20].
It is unresolved whether increased oxidative stress experiment and then every three weeks by tail plethys-
mography in conscious animals (experiment 2). At theplays a role in cardiovascular remodeling in renal insuf-
ficiency as well. To test this hypothesis we compared end of the experiment these animals were placed into
metabolic cages to collect 24-hour urine samples.SNX rats with and without treatment with dl--tocoph-
erol (vitamin E), a known antioxidant, and measured
Perfusion fixation and tissue samplingstructural parameters of the heart and central arteries.
Twelve weeks after the second operation the experi-
ment was terminated by retrograde perfusion fixation.
METHODS
The abdominal aorta was catheterized under Ketamin/
Animals Diazepam anesthesia (doses as above), and blood sam-
ples were taken for determination of Toco plasma levelsTwenty-eight male Sprague-Dawley rats (SD weighing
200 g; Ivanovas Co., Kisslegg, Germany) were housed in by high pressure liquid chromatography (HPLC; experi-
ment 1) or serum chemistry (experiment 2). The viscerasingle cages at constant temperature (20C) and humidity
(25%). The animals received a high protein (25%), low were rinsed with a 10% dextran solution containing 0.5
g/L procain-hydrochloride for two minutes. Ten secondssalt diet (0.5% NaCl) (Altromin Co., Lage, Germany).
After three days of adaptation, the animals were ran- after starting the aortic perfusion, the vena cava was
incised to drain the blood. After dextran infusion, thedomly allocated to moderate partial nephrectomy (SNX)
or sham operation (sham). vascular system was perfused with 0.2 mol/L phosphate
buffer containing 3% glutaraldehyde (experiment 1) or
Partial renal ablation by surgical ice-cold NaCl (experiment 2) for 12 minutes.
subtotal nephrectomy After the perfusion, the heart and the aorta of each
animal were taken out. In experiment 1 the heart and leftFirst, in animals with a subtotal nephrectomy (SNX),
the right kidney was removed under Ketamin/Diazepam ventricular weight and volume were determined. Tissue
samples and sections were obtained and stained ac-anesthesia (100 mg/kg or 2.5 g/kg, respectively) and the
weight of the kidney was determined. Control animals cording to the orientator method [21]. Uniformly ran-
dom sampling of the myocardium was achieved by pre-were sham operated, that is, the right kidney was decap-
sulated. Special care was taken to avoid damage to the paring a set of equidistant slices of the left ventricle and
the interventricular septum with a random start. Twoadrenals [6].
Seven days later, in the SNX group the cortex of the slices were selected by area weighted sampling and pro-
cessed accordingly. Eight pieces of the left ventricularleft kidney was partially resected, removing a quantity
corresponding to 2/3 of the weight of the previously muscle including the septum were prepared and after-
wards embedded in Epon-Araldite. Semithin sectionsresected right kidney. Again, sham operation of control
animals was performed by decapsulating the left kidney. (0.8m) were stained with methylen-blue and basic fuch-
sin and examined by light microscopy with oil immersion
Experimental protocol and phase contrast at a magnification of 1000:1 [6]. A
1-mm thick section of the aorta thoracica descendensBecause two different fixation procedures were used,
two separate experimental series were studied. The ani- was cut perpendicular to the vessel axis, and embedded
and sectioned as described above [6]. In addition, in twomals were randomly allocated to the following experi-
mental groups. animals per group, ultrathin sections (0.08 m) were
prepared and stained with uranyl acetate and lead citrateExperiment 1 (morphologic study). (1) Sham oper-
ated, untreated controls (sham, N  10). (2) Untreated and examined qualitatively with a Zeiss EM 10 electron
microscope (Zeiss Co., Oberkochen, Germany).SNX (SNX, N  9). (3) SNX dl--tocopherol (3000
IE/kg BW/week) (SNXToco, N  9). In experiment 2 the heart was taken out, weighed and
cut into three pieces perpendicular to the longitudinalExperiment 2 (biochemical study). (1) Sham-operated
untreated controls (sham, N  6). (2) Sham  dl-- axis. One piece was fixed in buffered formalin, the two
remaining pieces were snap frozen in isopentan-liquidtocopherol (3000 IE/kg BW/week) (sham  Toco, N 
7). (3) Untreated SNX (SNX, N  7). (4) SNX  dl-- nitrogen for immunohistochemistry and for biochemical
or molecular biological analysis, respectively.tocopherol (3000 IE/kg BW/week) (SNXToco, N 8).
The same protocol was used in both experimental se-
Stereological analysis (experiment 1)ries: Starting on day 3 after the second operation, dl--
tocopherol was administered with the food pellets twice Quantitative stereology. All investigations were per-
formed in a blinded manner, that is, the observer wasa week (1500 IE/kg/BW). Using a modified pair feeding
protocol special care was taken that the animals con- unaware of the animal’s study group. Stereological analy-
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Table 1. Animal data (experiment 1)
Systolic blood pressure Left ventricular Weighta of the left
Groups Hematocrit % mm Hg Body weight g weighta mg (remnant) kidney g
Untreated sham (N  10) 37.32.23 1006.74 3668.38 0.760.06 1.450.19
Untreated SNX (N  8) 32.63.79b 10711.7 35414.8 1.180.26b 1.350.20
SNX  Toco (N  8) 35.82.05 1028.48 3545.98 1.110.14b 1.430.16
Analysis of variance P  0.05 NS NS P  0.05 NS
Values are mean  standard deviation. Abbreviations are: sham, sham-operated control rats; SNX, subtotally nephrectomized rats; Toco, dl--tocopherol.
a Perfusion fixed tissue
b P  0.05 vs. untreated sham
sis was performed on eight random samples of differently
orientated sections of the left ventricular myocardium
per animal according to the orientator method [6, 21].
Length density (LV) of capillaries, that is, the length
of capillaries per unit tissue volume, and the volume
density (VV) of cardiac capillaries, defined as the volume
of capillaries per unit myocardial tissue volume, were
measured in eight systematically subsampled areas per
section using a Zeiss eyepiece with 100 points for point
counting. The length density of myocardial capillaries
(LV) was determined using the equation LV  2 QA
(where QA is area density, for example, the number of
capillary transects per area of myocardial reference tis-
sue) [6, 21]. Total capillary length per heart was calcu-
lated using the volume of the left ventricle (V) according
to the formula L  LV  V [6]. Intercapillary distance,
that is, the distance between the centers of two adjacent
Fig. 1. Systolic blood pressure values during the course of the studyintramyocardial capillaries, was calculated according to
in sham operated (sham) and dl--tocopheral (Toco)-treated subtotallya modification of the formula of Henquell and Honig as nephrectomized (SNX) rats (experiment 2). Symbols are: () sham;
described previously [6]. Volume density (VV) of the () sham  Toco; () SNX; () SNX  Toco. *P  0.05 vs. sham
operated groups.capillaries, interstitial tissue and myocytes was obtained
using the point counting method according to the equa-
tion PP  VV (where PP is point density). Reference
volume was the total myocardial tissue (exclusive of non-
sis of variance (ANOVA) was performed, followed bycapillary vessels, that is, arterioles and veins). Vascular
the least significant difference test to assess the differ-geometry of intramyocardial arteries, that is, wall thick-
ences between the groups. Results were considered sig-ness, lumen diameter, media and lumen area, was ana-
nificant when the probability of error (P) was less thanlyzed using a semiautomatic image analysis system (Vid-
0.05.eoplan; Kontron Co., Eching, Germany) as described in
detail [6, 22].
RESULTS
Immunohistochemical analysis
Description of the modelTo detect oxidative stress immunohistochemical inves-
Experiment 1. At the end of the 12 week experiment,tigations were performed on transversal paraffin sections
body weight, kidney weight and systolic blood pressureof the hearts (experiment 2) using an antibody against
values were comparable in all three experimental groups3-nitrotyrosine, which is a biomarker of peroxynitrite
(Table 1). The dl--tocopherol (Toco) plasma levelsformation (anti-3-NT, 1:400; Upstate Biotechnology,
were not significantly different between sham controlsLake Placid, NY, USA) as described in detail elsewhere
and untreated SNX rats. Treatment with Toco, however,[23, 24]. Negative controls were performed by omitting
led to a significantly higher plasma concentration of to-the primary antibody.
copherol (20.2  8.94 mg/L) versus untreated SNX
Statistics (14.6 3.67 mg/L) and sham control (11.6 1.21 mg/L).
While the hematocrit was significantly lower in untreatedAll data are expressed as mean  standard deviation.
After testing for normality of distribution one-way analy- SNX compared to sham controls, it was not significantly
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Table 2. Blood parameters (experiment 2)
Hemoglobin Serum Serum
Groups g/dL creatinine urea
Untreated sham (N  6) 15.30.45 0.510.03 41.25.55
Sham  Toco (N  6) 14.50.41 0.520.05 44.94.09
Untreated SNX (N  7) 14.10.68 0.690.05a 70.77.85a
SNX  Toco (N  8) 13.91.0 0.720.07a 77.611.8a
Analysis of variance NS P  0.05 P  0.05
Values are mean  standard deviation. Abbreviations are in Table 1.
a P  0.05 vs. untreated sham
lower in SNX treated with Toco. Absolute and relative
Fig. 2. Treatment with dl--tocopherol (Toco) abrogates the decrease
left ventricular weight (that is, left ventricular weight:body in capillary length density in subtotally nephrectomized (SNX) rats.
*P  0.05 vs. untreated sham operated controls (sham); P  0.05 vs.weight ratio) was significantly higher in both SNX groups
untreated SNX.(60.5% in untreated and 49.5% in Toco treated ani-
mals, respectively) compared to sham controls.
Experiment 2. Systolic blood pressure (Fig. 1), serum
chemistry and hemoglobin (Hb; Table 2) were not af- Ultrastructural examinations using electron micros-
fected by Toco treatment in sham or SNX animals, re- copy revealed marked structural alterations of the aortic
spectively. wall in SNX rats that included a reduced content of elas-
tic fibers and increased collagen fibers. In addition, in
Structural changes of the heart both SNX groups endothelial cells were markedly en-
larged and showed signs of cell activation with an increasedVolume density of the cardiac interstitial tissue (Table
number of vesicles. These ultrastructural changes were3) was significantly higher after SNX compared to sham
not affected by the treatment with Toco.controls; however, it was significantly lower in Toco
treated than in untreated SNX rats (	21.5%). The length Immunohistochemistry
density of capillaries (Fig. 2) was significantly less in SNX
Staining with the nitrosotyrosine antibody showed mildanimals than in sham controls (4574  1139 mm/mm3),
oxidative stress in cardiac myocytes and vascular smooth
and treatment with Toco (3664  600 mm/mm3) led to
muscle cells of the intramyocardial arteries of untreated
a significantly higher value compared to untreated SNX SNX rats (Fig. 4B) compared to practically no staining
animals (2244  424 mm/mm3). In parallel, the mean in sham control rats (Fig. 4A). Staining was less, how-
intercapillary distance was significantly higher in SNX ever, when SNX rats were treated with Toco (Fig. 4C)
than in sham op controls (16.3  2.01 m). The values and no staining was detectable when the primary anti-
were significantly lower after Toco treatment (SNX  body was omitted (Fig. 4D).
Toco, 17.9  1.39 vs. SNX, 23.0  2.2 m). The total
length of capillaries per left ventricle (Table 3) was sig-
DISCUSSIONnificantly lower in untreated SNX compared to sham op
The main finding of the present study is the observa-controls. In Toco treated SNX it was significantly higher
tion that treatment with the antioxidant dl--tocopherolthan in untreated SNX (53.6%) or even in sham con-
(Toco, vitamin E) prevented cardiomyocyte/capillarytrols (16.1%). The wall thickness of intramyocardial
mismatch in the left ventricle of rats with chronic renalarteries was significantly higher in both SNX groups than
failure. An additional finding is the observation that in-in sham op controls with no effect of Toco treatment
terstitial fibrosis of the heart was significantly less in(Fig. 3 and Table 3). The same was true for the area of
subtotally nephrectomized (SNX) rats treated with Toco.the arterial media, wall-to-lumen ratio, and media area-
These two findings support a role of oxidative stress in
to-lumen area ratio (data not given). the genesis of inadequate capillary growth and of inter-
stitial fibrosis of the heart in renal failure.
Structural and ultrastructural changes
The present study confirms previous observations of
of the aorta thoracica diminished capillary supply in the left ventricle of ani-
The areas of the media and lumen, wall thickness, mals with partial renal ablation [6, 8] and of uremic
lumen diameter and wall to lumen area of the aorta patients [7]. Even in early experimental renal failure
thoracica descendens were not significantly different be- and in patients with renal failure marked cardiovascular
structural abnormalities were found [7–9, 22]. It is oftween the three experimental groups (data not shown).
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Table 3. Effect of treatment with dl--tocopherol on structural alterations of the heart
VV of non-vascular Wall thickness of Wall-to-lumen ratio of
Groups interstitial tissue % Ltot of capillaries m intramyocardial arteries lm intramyocardial arteries lm/lm
Untreated sham (N  10) 1.490.32 3359967 6.222.83 0.110.06
Untreated SNX (N  8) 3.330.47a 2540747a 9.246.05a 0.170.12a
SNX  Toco(N  8) 2.650.28ab 3901849ab 10.95.41a 0.180.46a
Analysis of variance P  0.05 P  0.05 P  0.05 P  0.05
Values are mean standard deviation. Abbreviations are: sham, sham operated control rats; SNX, subtotally nephrectomized rats; VV, volume density; Ltot, total
length of left ventricular capillaries.
aP  0.05 vs. untreated sham
bP  0.05 vs. untreated SNX
interest that the capillary deficit was not seen in other Oxidative stress is known to increase sympathetic tone
[18]. Inadequately elevated sympathetic nerve activity isorgans of SNX rats (that is, the m. psoas, the liver]. This
abnormality therefore must be regarded as specific for found in experimental renal failure [35] as well as in
uremic patients [36]. In a previous study [6] the decreasethe heart muscle [25]. The most important functional
consequence of a relative decrease in myocardial capil- in capillary supply was prevented by administration of
the central sympatholytic agent moxonidine in uremiclary supply in the presence of a concomitant increase in
cardiomyocyte diameter is an increased intercapillary rats. Sympathetic activity was not measured in the pres-
ent study and we cannot formally exclude a role of sym-oxygen diffusion distance. Such capillary/myocyte mis-
match presumably renders the myocardium more sus- pathetic activity.
Using immunohistochemistry, only moderate oxida-ceptible to hypoxic injury [11, 26].
The following aspects of the study deserve some com- tive stress was detected in the myocardium of untreated
SNX rats, which is not surprising given the moderatement.
Since SBP measurements were performed by tail ple- degree of renal insufficiency in our model. It is plausible
that under these circumstances treatment with Toco isthysmography, we cannot formally exclude minor changes
in the SBP profile. In previous studies, however, we could sufficient to considerably reduce the amount of reactive
oxygen species (which may not be the case under condi-clearly dissociate the development of cardiac remodeling
from elevated SBP [27]. We also provided evidence for tions of massive oxidative stress). There is increasing
evidence that reactive oxygen species are important cellu-a pathogenetic role of the sympathetic nervous [6] and
the endothelin (ET) systems [28, 29]. For logistic reasons, lar signals that cause vascular remodeling [37]. The mito-
genic effects of oxidants are partially mediated throughonly one dose of Toco was used and a dose-response
curve could not be established. Treatment with Toco was generation of growth factors. Mitogens are potent stimu-
lators of oxidant generation. Consequently, there is thestarted on the third day after induction of renal failure.
Thus, the present study is a prevention study. One can possibility of a self-perpetuating mechanism involved in
atherogenesis and vascular remodeling. Oxidants shiftonly speculate about a potential effect of Toco on regres-
sion of the lesions, which presumably would be clinically the balance of the coagulation system toward platelet
aggregation and thrombus formation [38]. Ogata et almore important. Atherosclerotic lesions are not seen in
the model of renal failure by subtotal nephrectomy of the investigated the regulation of redox-sensitive genes by
nuclear factor-
B (NF-
B), which in turn is activatedrat and, therefore, it was not possible to address the im-
portant question of a possible effect of Toco on athero- by oxygen free radicals [39]. They found that protein
kinase C (PKC) is involved in the activation of NF-
Bsclerotic vascular changes such as fatty streak or plaque
formation. by superoxide anion in human endothelial cells.
In cultured retinal capillary cells, Jenkins et al docu-Since treatment with Toco increased the hematocrit
level in SNX rats of the experiment 1, it is possible that mented that pretreatment with vitamin E decreased en-
dothelin-1 (ET-1) levels [40]. This is of particular interestpart of the beneficial effects of the treatment was medi-
ated via correction of anemia. Anemia is a known cause in view of the recent finding that ET-1 mRNA and pro-
tein expression are increased in the heart of SNX ratsof LVH and cardiovascular dysfunction in renal failure
[30–32]. It has been proposed that oxidative stress short- [27, 28]. Treatment of SNX rats with selective and unse-
lective ET receptor blockers prevented cardiac remodel-ens red blood cells survival in uremia [33]. In a previous
study, however, we documented that correction of ane- ing and cardiomyocyte/capillary mismatch [27, 28].
In an experimental study in rats using the Langendorfmia by EPO prevented LVH, but did not affect capillary
supply [34]. preparation Venditti et al investigated the effect of vita-
min E on ischemia-reperfusion injury [41]. FunctionalIt is possible that the beneficial effects of Toco treat-
ment are mediated via the reduction of sympathetic tone. recovery of heart rate, left ventricular diastolic pressure
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Fig. 3. Myocardium of a sham operated control rat (A), an untreated
subtotally nephrectomized (SNX) rat (B), and a dl--tocopherol (Toco)
treated SNX rat (C). Semithin sections, magnification: 1:1000. The num-
ber of capillary profiles per area myocardium is lower in the untreated
SNX animal (B) compared to the control rat (A) or the Toco-treated
SNX rat (C), respectively. In contrast, thickening of the vascular wall
with hypertrophy of vascular smooth muscle cells in untreated SNX (B)
compared to controls (A) is not affected by treatment with Toco (C).
and coronary flow were significantly improved; the anti-
oxidant capacity and the response of heart homogenates
to in vitro oxidative stress were not affected. These re-
sults show a protective effect of vitamin E treatment
against lipid peroxidation and cardiac dysfunction after
ischemia-reperfusion injury. Sethi et al investigated the
effect of vitamin E therapy in acute myocardial infarction
in rats [42] and found a reduction in total mortality (from
38% to 16%) and infarct size (from 44.2% to 22.3%)
after treatment with vitamin E. In addition, the depres-
sion in left ventricular function was abrogated, sug-
gesting that vitamin E reduces oxidative stress in this
model. Effects of vitamin E treatment on oxidative stress
also may be the potential explanation for the results in
SNX rats.
Since we did not directly measure indices of oxidative
stress, it cannot be excluded that the beneficial action
of high doses of vitamin E was mediated by propertiesFig. 4. Immunohistochemical detection of oxidative stress in sham op-
of vitamin E unrelated to its action on redox potential.erated control rats (A), untreated (B) and Toco-treated (C ) subtotally
nephrectomized rats. Note that staining intensity is markedly higher in Although the HOPE study failed to show an effect of
cardiomyocytes and vascular smooth muscle cells of untreated SNX vitamin E therapy in high risk cardiovascular patientsrats (B) compared to sham operated controls (A) and Toco treated
SNX animals (C). (D) Negative control. [43], evidence has been provided that in patients on
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atherosclerosis in prolonged maintenance hemodialysis. N Engl Jhemodialysis (HD) or peritoneal dialysis, low density
Med 290:697–701, 1974
lipoproteins (LDL) are less susceptible to oxidation after 10. Schwarz U, Buzello M, Ritz E, et al: Morphology of coronary
vitamin E treatment [44]. There have been attempts to atherosclerotic lesions in patients with end-stage renal failure.
Nephrol Dial Transplant 15:218–223, 2000expose uremic patients to vitamin E-coated dialysis mem-
11. Ritz E, Amann K, To¨rnig J, et al: Some cardiac abnormalities inbranes [45] and at least one study showed beneficial renal failure, in Advances in Nephrology, edited by Gru¨nfeld JP,
effects [46]. Nevertheless, the role of vitamin E in the Bach JF, Kreis H, et al, St. Louis, Mosby, 1997, pp 85–97
12. Demuth K, Blacher J, Guerin AP, et al: Endothelin and cardiovas-management of uremic patients remains uncertain. In
cular remodelling in end-stage renal disease. Nephrol Dial Trans-the present study a very high dose of vitamin E was plant 13:375–383, 1998
administered and a hard end point, that is, the cardiac 13. Fiorillo C, Oliviero C, Rizzuti G, et al: Oxidative stress and
antioxidant defenses in renal patients receiving regular haemodial-structure, was evaluated. It is possible that our experi-
ysis. Clin Chem Lab Med 36:149–153, 1998mental study had a greater sensitivity to detect an action 14. Tetta C, Biasioli S, Schiavon R, et al: An overview of haemodial-
of vitamin E than the controversial clinical trials assessing ysis and oxidant stress. Blood Purif 17:118–126, 1999
15. Canaud B, Cristol J, Morena M, et al: Imbalance of oxidantsend points, the genesis of which are multifactorial.
and antioxidants in haemodialysis patients. Blood Purif 17:99–106,In conclusion, our experimental study provides evi-
1999
dence that supplementation of rats with moderate renal 16. Galli F, Canestrari F, Buoncristiani U: Biological effects of
oxidant stress in haemodialysis: The possible roles of vitamin E.failure with dl--tocopherol (vitamin E) abrogated cardi-
Blood Purif 17:79–94, 1999omyocyte/capillary mismatch and interstitial fibrosis of
17. Panzetta O, Cominacini L, Garbin U, et al: Increased susceptibil-
the heart, two structural abnormalities with potential ity of LDL to in vitro oxidation in patients on maintenance hemodi-
alysis: Effects of fish oil and vitamin E administration. Clin Nephrolrelevance for cardiac dysfunction, hypoxia intolerance
44:303–309, 1995and cardiac death in uremia.
18. Zanzinger J, Czachurski J: Chronic oxidative stress in the RVLM
modulates sympathetic control of circulation in pigs. Pflu¨gers Arch
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